Combination Therapy May Increase Lesion Closure in PCV - Takeaways - MDSpire

Combination Therapy May Increase Lesion Closure in PCV

The combination of photodynamic therapy and intravitreal  aflibercept did not improve 1-year visual acuity outcomes compared with aflibercept monotherapy.

  • By

  • Andrea Surnit

  • May 13, 2026

  • 3 min

Share

  • 1

    Combination therapy with reduced-fluence photodynamic therapy and aflibercept did not improve visual acuity compared to aflibercept alone.

  • 2

    The study showed higher early polypoidal lesion closure rates with combination therapy at week 12 compared to monotherapy.

  • 3

    At week 52, lesion closure rates were 73% for combination therapy versus 47% for monotherapy.

  • 4

    No serious adverse events were reported in either treatment group during the trial.

  • 5

    The study faced limitations due to a smaller sample size and delays, impacting the ability to draw definitive conclusions.

Original Source(s)

Combination Therapy May Increase Lesion Closure in PCV

  • by Andrea Surnit

  • May 13, 2026

Related Content

Nonexudative Macular Neovascularization in Age-Related Macular Degeneration

The Good News About AMD Prevention and Early Intervention

AMD severity is measured on a spectrum, and the sooner doctors, patients, and caregivers are aware of its presence, the sooner everyone can work together to protect against it. 

Supplying Ocular Nutritional Supplements

Supplying ocular nutritional supplements (ONS) is a way to deepen patient trust and improve their visual outcomes, with the byproduct a new revenue stream. This is the theme of this issue of Optometric Management.